MeiraGTx Holdings (MGTX) risk factors

78 risks, 10 new, 5 dropped, 19 reworded since the prior year. MeiraGTx continues to accumulate net losses, reaching an accumulated deficit of approximately $816.2 million as of December 31, 2025. The company added new risks covering artificial intelligence adoption, potential biosimilar competition, and environmental liabilities. Clinical and regulatory hurdles for its gene therapy platform and third-party dependencies remain central.

73 risks. MeiraGTx faces ongoing operating losses, relies heavily on milestone payments from Johnson & Johnson, and requires additional capital to fund clinical development.